RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17329Keywords:
allele-specific PCR, calreticulin, essential thrombocythemia, mutation., myeloproliferative neoplasmsAbstract
Background: Approximately 15% to 24% of essential thrombocythemia (ET) and 25–35% of primary myelofibrosis cases carry a mutation in the calreticulin (CALR) gene. Sanger sequencing, qPCR, high resolution melt or targeted next generation sequencing usually used to detect these mutations are expensive and require costly equipment. Nevertheless, type 1 CALR mutations are detectable by using polymerase chain reaction (PCR) and agarose gel electrophoresis. Aim: To offer the use of the allele-specific reverse transcription (RT) PCR for rapid low-cost detection of the type 2 mutation in the CALR gene. Materials and Methods: Allele-specific primers designed for detecting type 2 mutation (5-bp insertion; c.1154_1155 ins TTGTC) of the CALR gene were used for allele-specific RT-PCR analysis of cDNA of the patient with JAK2-, MPL-negative ET, whose mutation in CALR gene has been identified by Sanger sequencing. RT-PCR samples were analyzed by agarose gel electrophoresis. Results: The type 2 mutation (K385fs*47 ins5) in CALR gene was detected by Sanger sequencing in JAK2- and MPL-negative ET patient. The cDNA obtained was then re-analyzed by using allele-specific RT-PCR with newly designed primers. Normal and type 2 mutation alleles of the CALR gene were detected by gel electrophoresis. The results of allele-specific RT-PCR were consistent with the data of Sanger sequencing. Conclusion: Allele-specific RT-PCR analysis may be used for the fast low-cost detection of the major type 2 mutation (ins 5) of the CALR gene in patients with MPNs.
References
Verstovsek S, Tefferi A. Myeloproliferative Neoplasms: Biology and Therapy (Contemporary Hematology). Humana Press, 2011. 230 p. ISBN: 978-1-60761-266-7
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours), Fourth Edition. Lyon: IARC Press, 2008. 439 p. ISBN-13 9789283244943
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405. https://doi.org/10.1182/blood-2016-03-643544
Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005; 42: 230–8. https://doi.org/10.1053/j.seminhematol.2005.05.022
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61. https://doi.org/10.1016/s0140-6736(05)71142-9
Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97. https://doi.org/10.1016/j.ccr.2005.03.023
Pardanani A, Levine R, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–6. https://doi.org/10.1182/blood-2006-04-018879
Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–90. https://doi.org/10.1056/nejmoa1311347
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–405. https://doi.org/10.1056/nejmoa1312542
Tefferi A, Barbui B. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 94: 133–43. https://doi.org/10.1002/ajh.25303
Jones AV, Ward D, Lyon M, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leukemia 2015; 39: 82–7. https://doi.org/10.1016/j.leukres.2014.11.019
Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2015; 29: 249–52. https://doi.org/10.1038/leu.2014.270
Zinke M, Nageswaran V, Reinhardt R, et al. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR Mol Diagn Ther 2015; 19: 329–34. https://doi.org/10.1007/s40291-015-0162-3
Dybkov MV, Gartovska IR, Maliuta SS, et al. Detection of V617F mutation of gene jak2 at patients with chronic myeloproliferative neoplasms. Biopolym Cell 2010; 26: 214–7. http://dx.doi.org/10.7124/bc.000159
Gluzman DF, Sklyarenko LM, Zavelevich MP, et al. Complex diagnosis of myeloid neoplasms in regional oncological centers. Science and Innovation (Nauka Innov) 2013; 9: 61–72. http://dx.doi.org/10.15407/scin9.06.061
Gluzman DF, Sklyarenko LM, Telegeev GD, et al. Dia¬gnostics of acute leukemia and myeloproliferative neoplasms Scientific-practical guide. Kyiv: DIA, 2016. 124 p (in Russian). ISBN 978-617-7015-40-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
